MedPAC: Overhaul MA payments and streamline CMMI models

June 16, 2021Garrett SchmittNo CommentsCMMI, FFS, high-cost drugs, MA, MACPAC, Medicare, Medicare Advantage, MedPAC

Two influential advisory groups sent recommendations to Congress calling for a revamp of how health plans are paid in the lucrative Medicare Advantage program, culling how many models CMS tests and curbing high-cost drug approvals. By many measures, the MA program has been thriving. Enrollment and participation has continued to grow, and in 2021, MA…

Recent Posts

  • RECORDED WEBINAR: Understanding SDS Risk Adjustment and Why the Window for Health Plan Action Is Now
  • Single-Specialty Nephrology Networks: A Distinct Advantage in Value-Based | VBCEH Exclusive
  • Why value-based care and quality go hand in hand
  • Flawed Benchmark Policy Taxes Accountable Care’s Most Successful Providers
  • Expanding Medicare’s joint replacement model: Considerations for healthcare providers regarding the new CJR-X Model | Milliman MedInsight
 
  • Main Lobby
  • Exhibit Hall
  • Events
  • Exhibit With Us
  • Board Room
  • Library
  • Contact Us